A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
← catalyst calendarNCT06084884 · readout in 480 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
94estimated
Sites
19
Countries
Japan, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-14 | actual | When the study began enrolling |
| Primary completion | 2027-12-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-13 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Intervention
- Biological: AZD5851 — also filed as Cell Therapy
Primary outcome
what the primary-completion date above is the date OF1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase
measured Through study completion, an average of 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed